SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The 6-K discloses a regular cash dividend declaration by Super Group's Board on September 4, 2026, of 5¢ per ordinary share payable September 30, 2026. This is a routine but material capital distribution to shareholders; the filing explicitly reports the dividend declaration and notes year-to-date distributions totaling 15¢ per share, which is a material event affecting shareholder value and investor assessment.
View raw filing on EDGAR →PMI furnished a press release (Exhibit 99.1) disclosing updated 2026 full-year and Q3 diluted EPS forecasts, raising the full-year adjusted diluted EPS guidance range to $8.35–$8.50 (representing 10.7%–12.7% growth versus 2025). Although this is a guidance update rather than final results, it constitutes a material earnings disclosure furnished in connection with a conference presentation, consistent with Item 7.01 Regulation FD Disclosure practice for earnings-related announcements.
View raw filing on EDGAR →Strive announced a bitcoin purchase of 1,375 BTC at ~$79,281 per coin (totaling approximately $109 million) during August 31–September 4, 2026, along with updated holdings of cash, bitcoin, and equity securities. This represents a material capital deployment and treasury strategy execution that would affect investor assessment of the company's financial position and strategic direction, but does not fit neatly into debt issuance, M&A, impairment, or other specific financial categories. The disclosure is operational/strategic in nature—a treasury management and asset allocation decision—rather than a discrete financial event like a debt or equity issuance.
View raw filing on EDGAR →The filing discloses an unregistered sale of equity securities under Item 3.02, specifically the issuance of 1,254,839 Class S-PR shares and 1,206,139 Class I-PR shares for aggregate gross proceeds of approximately $20.4 million pursuant to Regulation D. This is a classic dilutive issuance of unregistered equity that would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →Cycurion announced approximately $800,000 in annual contract spend across multiple new commercial engagements, including a pharmaceutical AI Center of Excellence engagement and a NACCHO award. This represents execution of the company's stated commercial expansion strategy into healthcare and life sciences. While not a single discrete operational event like a major contract or partnership, the announcement of multiple material commercial wins that advance the company's strategic direction and demonstrate market traction constitutes a material operational disclosure warranting investor attention.
View raw filing on EDGAR →Braveheart Bio disclosed its unaudited financial results for the second quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes condensed statements of operations and comprehensive loss, balance sheets, and detailed financial metrics (R&D expenses of $11.1M, G&A expenses of $4.8M, net loss of $15.0M, and net loss per share of $2.51). This is a standard quarterly earnings release for a clinical-stage biopharmaceutical company, material to investors assessing the company's financial condition and cash runway (estimated to support operations into 2029).
View raw filing on EDGAR →The filing discloses approval and grant of fiscal year 2027 long-term incentive awards (PSUs and RSUs) to four named executive officers—William Stone (CEO), Michael Akkerman (CBO), Joshua Kinsell (Interim CFO), and Benneaser John (CTO)—under the Company's 2020 Equity Incentive Plan. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The awards total substantial equity grants with performance and time-based vesting conditions through June 2029.
View raw filing on EDGAR →Jeewat Bijlani, Executive Vice President and Chief Growth Officer, is departing the Company effective September 30, 2026, in a termination without cause. The disclosure centers on the departure itself and associated severance entitlements under his employment agreement. While severance terms are mentioned, the principal disclosed action is the executive leaving his role, making this an exec_departure rather than exec_compensation.
View raw filing on EDGAR →Quantinuum entered into a material definitive agreement with the U.S. Department of Commerce on September 4, 2026, securing up to $100 million in CHIPS Act funding for trapped-ion quantum computer manufacturing R&D. Under the agreement, the Department of Commerce received 2,369,528 shares of Class A common stock, representing a material capital infusion and equity issuance that affects the company's capital structure and strategic positioning in quantum computing.
View raw filing on EDGAR →The filing discloses the Board's declaration of multiple dividends: a monthly dividend of $0.13 per share on common stock and quarterly dividends on three series of preferred stock (Series B, C, and D), with specific payment and record dates. This is a routine but material dividend declaration typical of a REIT, affecting shareholder returns and investor valuation.
View raw filing on EDGAR →The filing discloses a declaration by the Board of Trustees of a monthly common distribution of $0.08 per share, payable on October 30, 2026 to shareholders of record as of September 30, 2026. This is a routine but material dividend declaration for a closed-end fund (Ellington Credit Company), which is a standard capital distribution to shareholders and would affect investor assessment of yield and total return.
View raw filing on EDGAR →Barnes & Noble Education issued a press release on September 8, 2026 announcing financial results for the fiscal quarter ended August 1, 2026, with detailed consolidated statements of operations showing revenue of $290.6 million, net loss of $12.9 million (improved 29% YoY), and Adjusted EBITDA of $(9.3) million (improved 19% YoY). The filing explicitly states the press release is furnished as Exhibit 99.1 and financial statements as Exhibit 99.2, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →Steven Hershkowitz, Executive Vice President and Chief Revenue Officer, resigned effective September 8, 2026 to pursue another opportunity. While the disclosure also mentions transfer of his responsibilities to Keith Costello (the COO), the principal disclosed action is Hershkowitz's departure from a named executive officer role. The CRO position is material to investor assessment of leadership continuity and revenue management.
View raw filing on EDGAR →Spyre announced positive Phase 2 SKYLINE trial topline data for SPY003 (anti-IL-23) in ulcerative colitis, demonstrating a statistically significant 10.0-point reduction in RHI score (p<0.0001) and clinical remission rates of 20%, meeting all key efficacy and safety objectives. This represents a material clinical development milestone and proof-of-concept for a key pipeline asset, advancing the company's combination strategy and strengthening its IBD program.
View raw filing on EDGAR →Simeon Kohl was appointed as Chief Executive Officer, President, principal executive officer, principal operating officer, and Board member of Health Catalyst, Inc., effective September 14, 2026. Ben Albert transitioned from CEO to Chief Business Officer in connection with this succession. Kohl brings over 20 years of healthcare leadership experience, including his track record at Performant Healthcare.
View raw filing on EDGAR →ServiceTitan issued a press release on September 8, 2026 announcing financial results for the fiscal second quarter ended July 31, 2026, including revenue of $292.8 million (21% YoY growth), GAAP operating loss of ($27.6) million, and non-GAAP free cash flow of $50.5 million. The filing includes condensed consolidated financial statements, forward guidance for Q3 and full-year FY2027, and management commentary from the Co-Founders and CEO. This is a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →This disclosure announces FDA approval of Etcamah (camizestrant) in combination with CDK4/6 inhibitors for first-line HR-positive breast cancer with emergent ESR1 mutations, based on positive Phase III SERENA-6 trial results showing 56% risk reduction in disease progression or death. While this is a significant regulatory and commercial milestone for AstraZeneca's oncology portfolio, it does not fit the specific event types of earnings_release, ma_activity, or other defined categories. It is a material operational/commercial event—a major product approval—that would affect investor assessment of the company's pipeline and market position, warranting operational_other classification.
View raw filing on EDGAR →Guardian Metal's admission to the FTSE AIM 50 Index effective 21 September 2026 is a significant operational and market milestone. The press release emphasizes this as "an important milestone on the journey" and reflects the company's momentum in tungsten exploration and development. While not a discrete transaction (M&A, debt issuance, or earnings event), index inclusion materially enhances the company's market profile, liquidity, and visibility to institutional investors, affecting a reasonable investor's assessment of the registrant's strategic position and market standing.
View raw filing on EDGAR →Smith & Nephew announces a cash tender offer to repurchase up to $250 million of its outstanding 2.032% Senior Notes due 2030, coupled with a concurrent offering of new senior notes due 2036. This is a material debt management transaction involving the creation of new direct financial obligations (the New Notes) and refinancing of existing debt, which would affect a reasonable investor's assessment of the company's capital structure and financial position.
View raw filing on EDGAR →This 6-K furnishes a press release announcing positive Phase III trial results for Imfinzi plus Imdelltra in small cell lung cancer, demonstrating "statistically significant and highly clinically meaningful improvement in overall survival" versus Imfinzi alone. While technically a clinical trial result rather than financial earnings, this disclosure functions as a material product/pipeline announcement that would affect investor assessment of AstraZeneca's oncology portfolio and commercial prospects. The language emphasizing "unprecedented improvement" and "new standards of care" signals material clinical and commercial significance.
View raw filing on EDGAR →The Federal Home Loan Bank of New York discloses the issuance of consolidated obligations (debt securities) totaling approximately $3.015 billion across multiple trade dates in September 2026, including variable-rate floaters and fixed-rate callable bonds. Item 2.03 explicitly covers "Creation of a Direct Financial Obligation," and Schedule A details specific bond and note issuances with CUSIP identifiers, settlement dates, maturity dates, and coupon rates, representing new direct financial obligations of the Bank.
View raw filing on EDGAR →IQSTEL announced a strategic partnership with IDILIO TV to distribute premium microdrama content through its existing telecommunications operator relationships, targeting 40 million potential mobile users by Q2 2027 and 500,000 gross subscribers by year-end 2027. This is a material operational and strategic initiative leveraging the company's existing telecom infrastructure to enter a higher-margin digital content distribution business, supported by a $5 million seed round for IDILIO TV. While not a traditional M&A transaction, it represents a significant strategic pivot and new business line that would affect investor assessment of the company's growth strategy and revenue diversification.
View raw filing on EDGAR →The Company announced a board-approved $5 million share repurchase program, which constitutes a return of capital to shareholders. Although the Item 8.01 disclosure also mentions receipt of a $20 million development milestone payment from Takeda, the principal disclosed action is the authorization and announcement of the repurchase program. Share repurchases are classified as dividend_distribution events under the taxonomy as they represent distributions or returns of capital to holders.
View raw filing on EDGAR →Braze issued a press release on September 8, 2026 announcing financial results for the fiscal quarter ended July 31, 2026, disclosing 26% year-over-year revenue growth to $227.2 million, record second quarter free cash flow of $22 million, and updated full-year guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →International Stem Cell Corporation completed the sale of 100% of the membership interests of its wholly-owned subsidiary Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. on September 1, 2026, for an adjusted purchase price of $25,250,000. This is a material disposition of a significant asset (a wholly-owned subsidiary) that would substantially affect the registrant's financial position and operations going forward, as evidenced by the pro forma financial statements showing elimination of LCT's substantial revenues and operations.
View raw filing on EDGAR →The Company exercised 279,330 warrants at $13.32 per share, generating $3.7 million in gross proceeds and resulting in the issuance of new common shares. This represents approximately 28% dilution to the pre-exercise share count, materially affecting the registrant's capital structure and ownership dilution.
View raw filing on EDGAR →The disclosure centers on compensatory arrangements for two named executives: David Wachsman (President) and Quinton Byron Hamlett (CFO/Vice President). The offer letters establish initial annual salaries ($360,000 and $270,000 respectively), eligibility for discretionary bonuses, and deferred payment terms contingent on funding. While the filing is under Item 5.02, the principal disclosed action is the establishment of compensation terms rather than a departure or appointment event.
View raw filing on EDGAR →John M. Sullivan has been appointed to VICI Properties' Board of Directors as an independent director, effective upon regulatory approvals. The disclosure centers on the principal action of a person taking a board role, with details on his committee assignments and qualifications. This is a clear exec_appointment event. The appointment is material as it affects board composition and governance at a large S&P 500 REIT.
View raw filing on EDGAR →GF entered into a Securities Issuance Agreement with the U.S. Department of Commerce on September 3, 2026, to issue 9,907,399 ordinary shares at $37.85 per share. This is a material issuance of equity securities that will dilute existing shareholders. While the purchaser is a government entity (not a typical private placement), the economic substance is a direct equity issuance creating new shares, which falls within the dilutive_issuance category. The materiality is clear given the share count and the involvement of a U.S. government agency in what appears to be a CHIPS Act or similar industrial policy transaction.
View raw filing on EDGAR →The Board declared a quarterly cash dividend of $0.32 per share ($1.28 annualized) payable on October 14, 2026. This is a routine but material dividend distribution to shareholders, typical for REITs, and would affect a reasonable investor's assessment of capital returns and cash flow allocation.
View raw filing on EDGAR →The disclosure centers on a comprehensive employment agreement with Carlos Iafigliola, the President and CEO, detailing his compensation package (base salary of $875,000, bonus targets of 90-135% of base, equity awards, perquisites), severance arrangements (2x base plus bonus pre-Change in Control, 2.99x post-Change in Control), and benefits. While Iafigliola was appointed CEO on May 18, 2026, the filing date is September 8, 2026, and the agreement is dated September 4, 2026—making this a formalization of compensatory arrangements rather than the initial appointment announcement. The extensive detail on compensation structure, severance multiples, and clawback provisions is characteristic of exec_compensation disclosures under Item 5.02(e).
View raw filing on EDGAR →This news release announces Aris Mining's commencement of construction of a permanent bridge across the Puruni River in Guyana as an early infrastructure initiative supporting the Toroparu Gold Project. The bridge is a material operational milestone—it represents a significant capital commitment and infrastructure development that strengthens logistics access to a key project in the company's portfolio. While not a discrete event type like M&A or workforce reduction, it is clearly an operational/strategic business development that would affect a reasonable investor's assessment of project advancement and capital deployment.
View raw filing on EDGAR →Curaleaf issued a fact sheet on September 8, 2026, addressing what it characterizes as misleading statements from Aurora Cannabis regarding Curaleaf's proposal to acquire Aurora. The disclosure centers on Curaleaf's pending acquisition offer—specifically defending the terms (45% premium, US$4.00–US$5.00 per share consideration structure) and responding to Aurora's board rejection and shareholder communications. This is a material M&A activity disclosure, as it relates to an active acquisition proposal and Curaleaf's public defense of deal terms to shareholders.
View raw filing on EDGAR →The filing discloses the appointment of Rob Myers, M.D., as Chief Medical Officer effective September 21, 2026, to succeed Joanne Quan, M.D. While the section also describes Dr. Quan's departure and associated severance arrangements, the principal announced action is the appointment of a new CMO to a named executive officer role. The appointment of a C-suite executive is material to investors assessing company leadership and continuity.
View raw filing on EDGAR →Jeffrey B. Lamkin resigned from the Board of Directors and the Audit Committee effective September 3, 2026. The filing explicitly states his decision to resign and the Board's subsequent reduction in size from nine to eight directors. The resignation letter confirms no disagreement with the Company, and the Board action to reduce size is a direct consequence of the departure. This is a clear director departure triggering governance changes.
View raw filing on EDGAR →Jeffrey Bertolini was appointed Chief Operating Officer of Carlsmed, Inc., effective September 8, 2026, by the Board of Directors on September 4, 2026. The appointment includes compensatory arrangements with a salary increase to $475,000, target incentive opportunity increased to 60%, and a grant of 50,000 stock options. Bertolini was promoted from Senior Vice President of Operational Excellence and brings senior leadership experience from major medical device companies including SI-BONE, NuVasive, and US Surgical.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the final results of StepStone Group's 2026 Annual Meeting of Stockholders held on September 8, 2026, including voting outcomes for three proposals: (1) election of seven directors, (2) ratification of Ernst & Young LLP as independent auditor, and (3) advisory Say-on-Pay vote. The filing presents detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, and broker non-votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →Mission Produce announced its fiscal Q3 2026 financial results on September 8, 2026, disclosing total revenue of $450 million (26% increase YoY), net loss of $6.5 million per diluted share, and adjusted net income of $0.18 per diluted share. The press release attached as Exhibit 99.1 contains comprehensive quarterly financial results, segment performance, and forward guidance, which is the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →DeFi Development Corp. entered into an underwriting agreement on September 3, 2026, and completed a public offering on September 8, 2026, to issue 1,375,000 shares of Variable Rate Series C Perpetual Preferred Stock ("CHAD Stock") at $8.00 per share, generating approximately $11 million in gross proceeds. Although technically preferred equity, CHAD functions as a debt-like instrument with fixed stated amounts ($10.00 per share), cumulative daily dividends (initially 13.0% per annum), redemption rights, and mandatory repurchase obligations upon fundamental change events, with proceeds deployed for SOL acquisition and strategic initiatives.
View raw filing on EDGAR →Kyle Callaway, the Chief Accounting Officer and principal accounting officer, resigned effective September 1, 2026. While the filing notes his departure was not due to disagreement over financial reporting or controls, the resignation of a principal accounting officer is a material executive departure that affects the registrant's financial reporting structure. The filing explicitly discloses the departure under Item 5.02 and addresses the succession plan (Atul Bagga assuming the role).
View raw filing on EDGAR →GRI Bio announced positive Phase 2a translational biomarker data from its GRI-0621 (oral tazarotene) study in idiopathic pulmonary fibrosis patients, demonstrating proof-of-concept across multiple mechanistic pillars (immune rebalancing, fibrolysis, lung repair, antitussive, GI-protection) and supporting advancement toward a pivotal Phase 2b/3 adaptive study.
View raw filing on EDGAR →The 6-K discloses the results of Cognyte's annual general meeting of shareholders held on September 3, 2026, with detailed vote tallies for two proposals: (1) re-election of three Class II directors (Dafna Sharir, Avi Cohen, and Matthew O'Neill), and (2) approval of Kesselman & Kesselman (PwC) as independent auditors for fiscal year 2027. The document explicitly presents voting results with votes in favor, against, and abstentions for each proposal, which is the hallmark of shareholder_vote_results disclosure.
View raw filing on EDGAR →The filing discloses a proposed all-share acquisition of 80 Mile plc by Greenland Energy Company, announced under Rule 2.4 of the City Code on Takeovers and Mergers. The transaction values 80 Mile at £61.48 million and represents a 42.86% to 64.18% premium to recent trading prices. This is a material M&A activity that would substantially affect the registrant's business and shareholder base, even though it remains subject to pre-conditions and is not yet a firm offer.
View raw filing on EDGAR →The filing discloses the appointment of Gildas Bonnier as Interim Chief Financial Officer effective September 4, 2026. Although the role is interim and a permanent CFO search is underway, the appointment of a principal financial officer is a material executive appointment that would affect investor assessment of the company's financial leadership and governance. The detailed biographical information and compensation terms ($10,000/month consulting fee) confirm this is a substantive appointment disclosure.
View raw filing on EDGAR →This disclosure reports management's unaudited estimate of net asset value (NAV) per share as of August 31, 2026, ranging from $9.52 to $9.62. For a closed-end fund or BDC like Sound Point Meridian Capital, NAV disclosure is a material financial metric that investors rely on to assess the fund's value and performance. While not a traditional earnings release or financial statement, this NAV estimate is a key financial metric material to investors' investment decisions.
View raw filing on EDGAR →InnovAge issued a press release on September 8, 2026 announcing financial results for the fiscal fourth quarter and full year ended June 30, 2026. The disclosure includes detailed financial metrics (total revenues of $989.7 million, net loss of $0.7 million, Adjusted EBITDA of $94.6 million), year-over-year comparisons, and forward-looking guidance for fiscal 2027. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →The filing discloses the departure of two senior executives: Chad M. Smith, President of Better Mortgage Corporation (a wholly owned subsidiary), and Barry Feierstein, Chief Operating Officer of the Company. Both separations were effectuated via mutual separation agreements in early September 2026. The loss of a COO and a subsidiary president, particularly when occurring simultaneously, is material to investors' assessment of management continuity and operational stability.
View raw filing on EDGAR →Copper Property CTL Pass Through Trust declared and disclosed a monthly cash distribution of $0.081790 per certificate, totaling $6,134,248.99, payable on September 10, 2026 to certificateholders of record as of September 9, 2026. The August 2026 monthly report details the cash sources, uses, and distribution components typical of a pass-through trust.
View raw filing on EDGAR →The filing discloses a Revised 2026 Annual Budget with aggregate budgeted expenses of $19,500,000, with the revision "primarily due to unanticipated legal costs related to litigation." While the specific litigation details are not elaborated, the material increase in budgeted expenses attributable to litigation costs constitutes a disclosure of a material legal event that would affect a reasonable investor's assessment of the Trust's financial obligations and operational costs. The litigation itself is the driver of the budget revision and thus the salient event.
View raw filing on EDGAR →This disclosure reports the removal of LNR Partners as special servicer and appointment of Torchlight Loan Services, LLC as successor special servicer effective September 8, 2026, pursuant to Section 6.08(a) of the Pooling and Servicing Agreement. While the filing is under Item 6.02 (Change of Servicer or Trustee), this is a governance/administrative change to the trust structure that would be material to certificateholders as it affects the entity responsible for servicing and administering specially serviced loans and REO properties. The extensive disclosure of Torchlight's qualifications, experience, and portfolio underscores the significance of this servicer transition.
View raw filing on EDGAR →